GEMCITABINE ACCORD 100 mg/ml
Sponsors
Janssen - Cilag International, Ipsen Bioscience Inc., Ipsen Bioscience Inc., Centre Hospitalier Universitaire Rouen
Conditions
Metastatic Pancreatic AdenocarcinomaMuscle-Invasive Urothelial Carcinoma (MIBC) of the Bladderresected pancreatic adenocarcinoma
Phase 2
Phase 3
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in
Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants
With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving
Radical Cystectomy
Active, not recruitingCTIS2023-507188-21-00
Start: 2021-04-20Target: 171Updated: 2025-09-25
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
CompletedCTIS2024-518303-21-00
Start: 2020-05-25End: 2025-02-18Target: 3Updated: 2024-10-17